| Project/Area Number |
21700712
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Applied health science
|
|---|
| Research Institution | National Institute of Health and Nutrition |
|---|
Principal Investigator |
TOUSEN Yuko National Institute of Health and Nutrition, 食品保健機能プログラム, 流動研究員 (20360092)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 骨粗鬆症 / 大豆イソフラボン / エクオール / 骨密度 / 破骨細胞 / 骨芽細胞 / アポトーシス / エストロゲン / 大豆イソフラボン代謝産物 / RAW264 / 栄養学 / 健康 / 男性骨粗鬆症 |
|---|
| Research Abstract |
The administration of equol (0.50 mg/day) for 4 weeks inhibited tibial bone loss, and markers of bone resorption tended to decrease in orchiectomized mice. Furthermore, equol significantly inhibited the osteoclast formation induced by RANKL (receptor activator of NF-kappaB ligand) in a dose-dependent manner (0.1-50 μM) in RAW 264 cells and promoted the activities of caspase 3/7 in RAW 264 cell-derived mature osteoclasts. These results suggest that equol improves the bone metabolism in male osteoporotic patients, and the inhibition of bone resorption may contribute to the improvement of bone metabolism.
|
